Novartis’ remibrutinib shows promise for patients with CSU
Highly selective inhibitor therapy treats patients with chronic spontaneous urticaria
Read More
Tag: hives
- Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
- Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
- KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
- Pepaxti study supports use in wider myeloma population
- UCB reports positive outcomes for bimekizumab in psoriatic arthritis
